603998.SH
Hunan Fangsheng Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 10.51
+1.15%Oct 28, 2026, 11:04 UTC
Fangsheng Pharmaceutical said its subsidiary Xiangya Pharmaceutical plans to acquire 70% of the preclinical technology and results for Sanhua Qingjie Granules from related party Fangsheng Rongke for RMB 9.8 million and continue development through collaborative research.
Source:Oct 16, 2026, 10:08 UTC
China’s National Medical Products Administration approved Fangsheng Pharmaceutical’s adenosylcobalamin capsules and issued a drug registration certificate.
Source:Aug 31, 2026, 09:12 UTC
Fangsheng Pharmaceutical announced a cash dividend of 0.20 yuan per share for the first half of 2026, with total payout estimated at 88 million yuan, representing 44.43% of net profit attributable to shareholders.
Source: